ReviewHuman genomics2026
Inflammatory networks between adipose tissue, liver and pancreatic islets in type 2 diabetes.
Review in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2D) is no longer viewed solely as a metabolic disorder but rather as a chronic, low-grade inflammatory disease shaped by the interplay of immune signaling and metabolic stress across key organs. This study explored inflammatory molecular signatures in pancreatic islets, adipose tissue (AT), and liver associated with T2D. Publicly available human genomic and transcriptomic datasets were identified through a PubMed search. Differentially expressed genes and all identified non-coding RNAs (ncRNAs) from the three tissues were subjected to bioinformatic and enrichment analyses to identify tissue-specific and common inflammatory mediators. Through integrative multi-omics and functional analyses, we delineated both shared and tissue-specific inflammatory circuits in pancreatic islets, liver, and AT, highlighting the convergence of cytokine networks, particularly TNF-α, IL-6 and IL-17, as potential mediators of inter-organ dysfunction. These cytokines can contribute to a pathological feedback loop whereby inflammatory cues originating in AT propagate to pancreatic and hepatic compartments, compounding insulin resistance and β-cell failure. AKT1, MAPK3, and CCL2 may represent key cross-tissue effectors linking inflammatory signaling and metabolic control, whose activity is also sensitive to age-related molecular drift and stress response imbalances. Additionally, ncRNAs such as miR-3064 and miR-21 emerged as potential key post-transcriptional regulators of NF-κB, IL-6 and IL-17 signaling pathways, supporting the notion that epigenetic and transcriptomic reprogramming is involved in metabolic inflammation. Overall, our findings suggest a multi-layered inflammatory architecture underlying T2D, highlighting inflammatory mediators and regulatory RNAs as potential targets for precision therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.